{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:02:20Z","timestamp":1779811340975,"version":"3.53.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11991-9","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:32:24Z","timestamp":1779802344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive insight into nimbolide response against breast cancer treatment: present evidence, emerging strategy and future direction"],"prefix":"10.1007","volume":"53","author":[{"given":"Ayana","family":"Sarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya Swarupa","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeb Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"3","key":"11991_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"11991_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M et al (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"issue":"1","key":"11991_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X et al (2025) Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 10(1):49","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"11991_CR4","first-page":"288","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast Cancer Treatment: Rev Jama 321(3):288\u2013300","journal-title":"Breast Cancer Treatment: Rev Jama"},{"issue":"10087","key":"11991_CR5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415\u20132429","journal-title":"Lancet"},{"key":"11991_CR6","doi-asserted-by":"publisher","first-page":"175883592095835","DOI":"10.1177\/1758835920958354","volume":"12","author":"KJ Lee","year":"2020","unstructured":"Lee KJ et al (2020) Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Ther Adv Med Oncol 12:1758835920958354","journal-title":"Ther Adv Med Oncol"},{"key":"11991_CR7","doi-asserted-by":"publisher","first-page":"701073","DOI":"10.3389\/fcell.2021.701073","volume":"9","author":"M Guo","year":"2021","unstructured":"Guo M, Wang SM (2021) Genome Instability-Derived Genes Are Novel Prognostic Biomarkers for Triple-Negative Breast Cancer. Front Cell Dev Biol 9:701073","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"11991_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/nop2.737","volume":"8","author":"H Xu","year":"2021","unstructured":"Xu H et al (2021) Development of health behaviour questionnaire for breast cancer women in Mainland China. Nurs Open 8(3):1209\u20131219","journal-title":"Nurs Open"},{"issue":"4","key":"11991_CR9","first-page":"670","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging Biol Principles Metastasis Cell 168(4):670\u2013691","journal-title":"Emerging Biol Principles Metastasis Cell"},{"key":"11991_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fendo.2019.00245","volume":"10","author":"A Rani","year":"2019","unstructured":"Rani A et al (2019) Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. Front Endocrinol (Lausanne) 10:245","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"11991_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41419-021-04114-8","volume":"12","author":"H Luo","year":"2021","unstructured":"Luo H et al (2021) CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1. Cell Death Dis 12(9):820","journal-title":"Cell Death Dis"},{"key":"11991_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/plants11020193","author":"MA Moroole","year":"2022","unstructured":"Moroole MA et al (2022) Phytochemical profile, safety and efficacy of a herbal mixture used for contraception by traditional health practitioners in Ngaka Modiri Molema District Municipality, South Africa. Plants (Basel). https:\/\/doi.org\/10.3390\/plants11020193","journal-title":"Plants (Basel)"},{"key":"11991_CR13","doi-asserted-by":"publisher","first-page":"1184472","DOI":"10.3389\/fphar.2023.1184472","volume":"14","author":"M Chaurasia","year":"2023","unstructured":"Chaurasia M et al (2023) A review of FDA approved drugs and their formulations for the treatment of breast cancer. Front Pharmacol 14:1184472","journal-title":"Front Pharmacol"},{"issue":"11","key":"11991_CR14","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1021\/acs.molpharmaceut.3c00286","volume":"20","author":"P Sa","year":"2023","unstructured":"Sa P et al (2023) Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights. Mol Pharm 20(11):5254\u20135277","journal-title":"Mol Pharm"},{"issue":"6","key":"11991_CR15","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.3390\/molecules19066929","volume":"19","author":"H Kato-Noguchi","year":"2014","unstructured":"Kato-Noguchi H et al (2014) Nimbolide B and nimbic acid B, phytotoxic substances in neem leaves with allelopathic activity. Molecules 19(6):6929\u20136940","journal-title":"Molecules"},{"key":"11991_CR16","doi-asserted-by":"crossref","unstructured":"Rajendran P et al (2024) Nimbolide: promising agent for prevention and treatment of chronic diseases (recent update). Food Nutr Res, 68","DOI":"10.29219\/fnr.v68.9650"},{"key":"11991_CR17","doi-asserted-by":"publisher","first-page":"e402125","DOI":"10.1590\/acb402125","volume":"40","author":"Y Gu","year":"2025","unstructured":"Gu Y et al (2025) Chemoprotective effect of nimbolide against N-methyl-N-nitrosourea induced gastric cancer via alteration of apoptosis and NF-\u03baB signaling pathway. Acta Cir Bras 40:e402125","journal-title":"Acta Cir Bras"},{"issue":"11","key":"11991_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/ars.2015.6418","volume":"24","author":"J Zhang","year":"2016","unstructured":"Zhang J et al (2016) Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model. Antioxid Redox Signal 24(11):575\u2013589","journal-title":"Antioxid Redox Signal"},{"key":"11991_CR19","doi-asserted-by":"publisher","first-page":"102031","DOI":"10.1016\/j.omtn.2023.102031","volume":"34","author":"P Mohapatra","year":"2023","unstructured":"Mohapatra P et al (2023) Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt\/\u03b2-catenin signaling axis. Mol Ther Nucleic Acids 34:102031","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"11991_CR20","doi-asserted-by":"publisher","first-page":"23405","DOI":"10.3390\/ijms161023405","volume":"16","author":"JF Liu","year":"2015","unstructured":"Liu JF et al (2015) Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma. Int J Mol Sci 16(10):23405\u201323424","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11991_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12885-023-11625-4","volume":"23","author":"A Senrung","year":"2023","unstructured":"Senrung A et al (2023) In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma. BMC Cancer 23(1):1173","journal-title":"BMC Cancer"},{"key":"11991_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020887","author":"A Kumar","year":"2023","unstructured":"Kumar A et al (2023) Major phytochemicals: recent advances in health benefits and extraction method. Molecules. https:\/\/doi.org\/10.3390\/molecules28020887","journal-title":"Molecules"},{"key":"11991_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/plants13040523","author":"EV Rodr\u00edguez-Negrete","year":"2024","unstructured":"Rodr\u00edguez-Negrete EV et al (2024) Phytochemicals and their usefulness in the maintenance of health. Plants (Basel). https:\/\/doi.org\/10.3390\/plants13040523","journal-title":"Plants (Basel)"},{"issue":"1","key":"11991_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ptr.8376","volume":"39","author":"ZA Bhutta","year":"2025","unstructured":"Bhutta ZA, Choi KC (2025) Phytochemicals as novel therapeutics for triple-negative breast cancer: a comprehensive review of current knowledge. Phytother Res 39(1):364\u2013396","journal-title":"Phytother Res"},{"key":"11991_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051100","author":"S Kamran","year":"2022","unstructured":"Kamran S et al (2022) Therapeutic potential of certain terpenoids as anticancer agents: a scoping review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14051100","journal-title":"Cancers (Basel)"},{"key":"11991_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom13121725","author":"Q Wang","year":"2023","unstructured":"Wang Q et al (2023) Functions of representative terpenoids and their biosynthesis mechanisms in medicinal plants. Biomolecules. https:\/\/doi.org\/10.3390\/biom13121725","journal-title":"Biomolecules"},{"issue":"7","key":"11991_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S2221-1691(13)60105-7","volume":"3","author":"VS Kumar","year":"2013","unstructured":"Kumar VS, Navaratnam V (2013) Neem (Azadirachta indica): prehistory to contemporary medicinal uses to humankind. Asian Pac J Trop Biomed 3(7):505\u2013514","journal-title":"Asian Pac J Trop Biomed"},{"issue":"5","key":"11991_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.tiv.2014.04.011","volume":"28","author":"LN Bodduluru","year":"2014","unstructured":"Bodduluru LN et al (2014) Chemopreventive and therapeutic effects of nimbolide in cancer: the underlying mechanisms. Toxicol Vitro 28(5):1026\u20131035","journal-title":"Toxicol Vitro"},{"issue":"2","key":"11991_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1568011053174828","volume":"5","author":"R Subapriya","year":"2005","unstructured":"Subapriya R, Nagini S (2005) Medicinal properties of neem leaves: a review. Curr Med Chem Anti-Cancer Agents 5(2):149\u2013146","journal-title":"Curr Med Chem Anti-Cancer Agents"},{"issue":"4","key":"11991_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5808\/GI.2014.12.4.156","volume":"12","author":"P Elumalai","year":"2014","unstructured":"Elumalai P, Arunakaran J (2014) Review on molecular and chemopreventive potential of nimbolide in cancer. Genomics Inf 12(4):156\u2013164","journal-title":"Genomics Inf"},{"issue":"14","key":"11991_CR31","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2174\/1871520622666220204115151","volume":"22","author":"R Nivetha","year":"2022","unstructured":"Nivetha R et al (2022) Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1\/PI3K\/Akt Signalling. Anticancer Agents Med Chem 22(14):2619\u20132636","journal-title":"Anticancer Agents Med Chem"},{"key":"11991_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.tiv.2018.05.010","volume":"51","author":"V Pooladanda","year":"2018","unstructured":"Pooladanda V et al (2018) Nimbolide epigenetically regulates autophagy and apoptosis in breast cancer. Toxicol Vitro 51:114\u2013128","journal-title":"Toxicol Vitro"},{"issue":"11","key":"11991_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41419-018-1126-4","volume":"9","author":"J Sophia","year":"2018","unstructured":"Sophia J et al (2018) Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K\/Akt\/GSK-3\u03b2 signalling pathway in oral cancer. Cell Death Dis 9(11):1087","journal-title":"Cell Death Dis"},{"issue":"45","key":"11991_CR34","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.3748\/wjg.v26.i45.7131","volume":"26","author":"AK Ram","year":"2020","unstructured":"Ram AK, Vairappan B, Srinivas BH (2020) Nimbolide inhibits tumor growth by restoring hepatic tight junction protein expression and reduced inflammation in an experimental hepatocarcinogenesis. World J Gastroenterol 26(45):7131\u20137152","journal-title":"World J Gastroenterol"},{"issue":"9","key":"11991_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/mc.22832","volume":"57","author":"MJ Patel","year":"2018","unstructured":"Patel MJ et al (2018) A supercritical CO(2) extract of neem leaf (A. indica) and its bioactive liminoid, nimbolide, suppresses colon cancer in preclinical models by modulating pro-inflammatory pathways. Mol Carcinog 57(9):1156\u20131165","journal-title":"Mol Carcinog"},{"issue":"12","key":"11991_CR36","doi-asserted-by":"publisher","first-page":"119344","DOI":"10.1016\/j.bbamcr.2022.119344","volume":"1869","author":"J Zhang","year":"2022","unstructured":"Zhang J et al (2022) Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-\u03baB signaling pathway in prostate cancer preclinical models. Biochim Biophys Acta Mol Cell Res 1869(12):119344","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"11991_CR37","doi-asserted-by":"publisher","first-page":"153826","DOI":"10.1016\/j.phymed.2021.153826","volume":"94","author":"N Mahmoud","year":"2022","unstructured":"Mahmoud N et al (2022) Nimbolide inhibits 2D and 3D prostate cancer cells migration, affects microtubules and angiogenesis and suppresses B-RAF\/p.ERK-mediated in vivo tumor growth. Phytomedicine 94:153826","journal-title":"Phytomedicine"},{"issue":"1","key":"11991_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12010-023-04507-9","volume":"196","author":"X Chen","year":"2024","unstructured":"Chen X et al (2024) Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells. Appl Biochem Biotechnol 196(1):182\u2013202","journal-title":"Appl Biochem Biotechnol"},{"issue":"16","key":"11991_CR39","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-13-0080","volume":"19","author":"SC Gupta","year":"2013","unstructured":"Gupta SC et al (2013) Nimbolide, a limonoid triterpene, inhibits growth of human colorectal cancer xenografts by suppressing the proinflammatory microenvironment. Clin Cancer Res 19(16):4465\u20134476","journal-title":"Clin Cancer Res"},{"issue":"6","key":"11991_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3109\/10715761003692503","volume":"44","author":"RV Priyadarsini","year":"2010","unstructured":"Priyadarsini RV et al (2010) The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells. Free Radic Res 44(6):624\u2013634","journal-title":"Free Radic Res"},{"key":"11991_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12101791","author":"T Mehmetoglu-Gurbuz","year":"2023","unstructured":"Mehmetoglu-Gurbuz T et al (2023) Nimbolide inhibits SOD2 to control pancreatic ductal adenocarcinoma growth and metastasis. Antioxidants. https:\/\/doi.org\/10.3390\/antiox12101791","journal-title":"Antioxidants"},{"issue":"43","key":"11991_CR42","doi-asserted-by":"publisher","first-page":"eadg7752","DOI":"10.1126\/sciadv.adg7752","volume":"9","author":"P Li","year":"2023","unstructured":"Li P et al (2023) Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer. Sci Adv 9(43):eadg7752","journal-title":"Sci Adv"},{"key":"11991_CR43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omto.2021.02.014","volume":"20","author":"A Arumugam","year":"2021","unstructured":"Arumugam A, Subramani R, Lakshmanaswamy R (2021) Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide. Mol Ther Oncolytics 20:596\u2013606","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"11991_CR44","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cbf.3040","volume":"32","author":"P Elumalai","year":"2014","unstructured":"Elumalai P et al (2014) Nimbolide inhibits IGF-I-mediated PI3K\/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231). Cell Biochem Funct 32(5):476\u2013484","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"11991_CR45","first-page":"247","volume":"1846","author":"F Hao","year":"2014","unstructured":"Hao F et al (2014) Neem components as potential agents for cancer prevention and treatment. Biochim Biophys Acta 1846(1):247\u2013257","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"11991_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12032-024-02379-5","volume":"41","author":"S Shaheen","year":"2024","unstructured":"Shaheen S et al (2024) Insights into Nimbolide molecular crosstalk and its anticancer properties. Med Oncol 41(6):158","journal-title":"Med Oncol"},{"key":"11991_CR47","doi-asserted-by":"publisher","first-page":"888079","DOI":"10.3389\/fphar.2022.888079","volume":"13","author":"ME Palmer","year":"2022","unstructured":"Palmer ME et al (2022) The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review. Front Pharmacol 13:888079","journal-title":"Front Pharmacol"},{"key":"11991_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030123","author":"L Wang","year":"2018","unstructured":"Wang L et al (2018) A sensitive liquid chromatography-tandem mass spectrometry method for the determination of nimbolide in mouse serum: application to a preclinical pharmacokinetics study. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics10030123","journal-title":"Pharmaceutics"},{"key":"11991_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jchromb.2018.06.002","volume":"1092","author":"SM Baira","year":"2018","unstructured":"Baira SM et al (2018) First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC\/MS method. J Chromatogr B Anal Technol Biomed Life Sci 1092:191\u2013198","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"1","key":"11991_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mpmed.2023.10.008","volume":"52","author":"SRJM Maxwell","year":"2024","unstructured":"Maxwell SRJM (2024) Pharmacodynamics and pharmacokinetics for the prescriber. Medicine Baltimore 52(1):1\u201310","journal-title":"Medicine Baltimore"},{"issue":"2","key":"11991_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0378-4274(86)90098-6","volume":"30","author":"T Glinsukon","year":"1986","unstructured":"Glinsukon T et al (1986) Acute toxicity of nimbolide and nimbic acid in mice, rats and hamsters. Toxicol Lett 30(2):159\u201366","journal-title":"Toxicol Lett"},{"key":"11991_CR52","unstructured":"Baligar NS et al (2014) Evaluation of acute toxicity of neem active constituent, nimbolide and its hepatoprotective activity against acute dose of carbon tetrachloride treated albino rats. 5(8):3455"},{"issue":"13","key":"11991_CR53","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0024-3205(96)00061-6","volume":"58","author":"E Cohen","year":"1996","unstructured":"Cohen E, Quistad GB, Casida JE (1996) Cytotoxicity of nimbolide, epoxyazadiradione and other limonoids from neem insecticide. Life Sci 58(13):1075\u20131081","journal-title":"Life Sci"},{"key":"11991_CR54","doi-asserted-by":"crossref","unstructured":"Trivedi A, Ahmad R, A.J.E.J.o.I M, Misra (2018) Effect of alkaline pH on cytotoxicity profile of neem (Azadirachta indica) ethanolic extract against human breast cancer cell line MDA-MB-231. 24:1\u20137","DOI":"10.1016\/j.eujim.2018.10.004"},{"issue":"8","key":"11991_CR55","doi-asserted-by":"publisher","first-page":"e2527805","DOI":"10.1001\/jamanetworkopen.2025.27805","volume":"8","author":"P Mathur","year":"2025","unstructured":"Mathur P et al (2025) Cancer Incidence and Mortality Across 43 Cancer Registries in India. JAMA Netw Open 8(8):e2527805","journal-title":"JAMA Netw Open"},{"key":"11991_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090957","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A (2019) Mechanisms of chemotherapy resistance in triple-negative breast cancer-How we can rise to the challenge. Cells Basel. https:\/\/doi.org\/10.3390\/cells8090957","journal-title":"Cells Basel"},{"key":"11991_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L et al (2021) Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat 54:100742","journal-title":"Drug Resist Updat"},{"issue":"14","key":"11991_CR58","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2217\/nnm-2024-0098","volume":"19","author":"S Sahoo","year":"2024","unstructured":"Sahoo S, Sahoo SK (2024) Phytonanomedicine as a therapeutic regulator of the tumor microenvironment for inhibiting cancer metastasis. Nanomed (Lond) 19(14):1227\u20131229","journal-title":"Nanomed (Lond)"},{"key":"11991_CR59","doi-asserted-by":"crossref","unstructured":"Mohapatra P et al (2022) Phytochemical based nanomedicine: A panacea for cancer treatment, present status and future prospective. 7:p100055","DOI":"10.1016\/j.onano.2022.100055"},{"key":"11991_CR60","doi-asserted-by":"crossref","unstructured":"Sharma T et al (2022) Advancements in clinical translation of flavonoid nanoparticles for cancer treatment. 8:p100074","DOI":"10.1016\/j.onano.2022.100074"},{"key":"11991_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10010006","author":"CD Suraweera","year":"2020","unstructured":"Suraweera CD, Hinds MG, Kvansakul M (2020) Poxviral strategies to overcome host cell apoptosis. Pathogens Basel. https:\/\/doi.org\/10.3390\/pathogens10010006","journal-title":"Pathogens Basel"},{"issue":"3","key":"11991_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.seminoncol.2021.05.002","volume":"48","author":"MA Shah","year":"2021","unstructured":"Shah MA, Rogoff HA (2021) Implications of reactive oxygen species on cancer formation and its treatment. Semin Oncol 48(3):238\u2013245","journal-title":"Semin Oncol"},{"issue":"2","key":"11991_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.toxlet.2012.10.008","volume":"215","author":"P Elumalai","year":"2012","unstructured":"Elumalai P et al (2012) Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett 215(2):131\u201342","journal-title":"Toxicol Lett"},{"issue":"12","key":"11991_CR64","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1080\/15548627.2021.1912270","volume":"17","author":"X Li","year":"2021","unstructured":"Li X et al (2021) CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy 17(12):4323\u20134340","journal-title":"Autophagy"},{"issue":"2","key":"11991_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12282-023-01541-7","volume":"31","author":"T Yu","year":"2024","unstructured":"Yu T et al (2024) Advances in the study of autophagy in breast cancer. Breast Cancer 31(2):195\u2013204","journal-title":"Breast Cancer"},{"issue":"10","key":"11991_CR66","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.devcel.2023.03.013","volume":"58","author":"P Popli","year":"2023","unstructured":"Popli P et al (2023) Beclin-1-dependent autophagy, but not apoptosis, is critical for stem-cell-mediated endometrial programming and the establishment of pregnancy. Dev Cell 58(10):885\u2013897e4","journal-title":"Dev Cell"},{"key":"11991_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2015.00059","volume":"6","author":"SM Farabaugh","year":"2015","unstructured":"Farabaugh SM, Boone DN, Lee AV (2015) Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol (Lausanne) 6:59","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"11991_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri SK et al (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2(1):13\u201325","journal-title":"Genes Dis"},{"issue":"1","key":"11991_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","volume":"12","author":"X Tan","year":"2023","unstructured":"Tan X et al (2023) Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol 12(1):83","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"11991_CR70","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cpr.12148","volume":"47","author":"P Elumalai","year":"2014","unstructured":"Elumalai P et al (2014) Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines. Cell Prolif 47(6):540\u2013552","journal-title":"Cell Prolif"},{"key":"11991_CR71","doi-asserted-by":"publisher","first-page":"117585","DOI":"10.1016\/j.biopha.2024.117585","volume":"180","author":"P Lorenc","year":"2024","unstructured":"Lorenc P et al (2024) Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF\/VEGFR pathway. Biomed Pharmacother 180:117585","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"11991_CR72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-017-0923-5","volume":"19","author":"EM De Francesco","year":"2017","unstructured":"De Francesco EM et al (2017) GPER mediates the angiocrine actions induced by IGF1 through the HIF-1\u03b1\/VEGF pathway in the breast tumor microenvironment. Breast Cancer Res 19(1):129","journal-title":"Breast Cancer Res"},{"issue":"2","key":"11991_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10456-011-9206-4","volume":"14","author":"R Tammali","year":"2011","unstructured":"Tammali R et al (2011) Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 14(2):209\u2013221","journal-title":"Angiogenesis"},{"issue":"1","key":"11991_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2004.05.024","volume":"217","author":"E Azenshtein","year":"2005","unstructured":"Azenshtein E et al (2005) The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 217(1):73\u201386","journal-title":"Cancer Lett"},{"issue":"3\u20134","key":"11991_CR75","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10555-007-9068-9","volume":"26","author":"S Singh","year":"2007","unstructured":"Singh S, Sadanandam A, Singh RK (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26(3\u20134):453\u2013467","journal-title":"Cancer Metastasis Rev"},{"key":"11991_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179302","author":"A Kotsifaki","year":"2024","unstructured":"Kotsifaki A et al (2024) Decoding the role of Insulin-like Growth Factor 1 and its isoforms in breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25179302","journal-title":"Int J Mol Sci"},{"key":"11991_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-015-0291-7","volume":"14","author":"PF Christopoulos","year":"2015","unstructured":"Christopoulos PF, Msaouel P, Koutsilieris M (2015) The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 14:43","journal-title":"Mol Cancer"},{"key":"11991_CR78","doi-asserted-by":"publisher","first-page":"155620","DOI":"10.1016\/j.prp.2024.155620","volume":"263","author":"S Kumar","year":"2024","unstructured":"Kumar S, Chaudhri S (2024) Recent update on IGF-1\/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer. Pathol Res Pract 263:155620","journal-title":"Pathol Res Pract"},{"issue":"8","key":"11991_CR79","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","volume":"20","author":"EE Patton","year":"2021","unstructured":"Patton EE, Zon LI, Langenau DM (2021) Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat Rev Drug Discov 20(8):611\u2013628","journal-title":"Nat Rev Drug Discov"},{"key":"11991_CR80","doi-asserted-by":"publisher","first-page":"1483192","DOI":"10.3389\/fimmu.2024.1483192","volume":"15","author":"C Hu","year":"2024","unstructured":"Hu C et al (2024) Advantages of the zebrafish tumor xenograft model: the evaluation of efficacy in cancer therapy and the application to the study of lncRNAs. Front Immunol 15:1483192","journal-title":"Front Immunol"},{"issue":"1","key":"11991_CR81","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","volume":"82","author":"SK Sahoo","year":"2002","unstructured":"Sahoo SK et al (2002) Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82(1):105\u2013114","journal-title":"J Control Release"},{"issue":"1","key":"11991_CR82","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.nano.2006.11.008","volume":"3","author":"SK Sahoo","year":"2007","unstructured":"Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. Nanomedicine Lond 3(1):20\u201331","journal-title":"Nanomedicine Lond"},{"issue":"4","key":"11991_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12032-025-02641-4","volume":"42","author":"DD Shah","year":"2025","unstructured":"Shah DD et al (2025) Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies. Med Oncol 42(4):117","journal-title":"Med Oncol"},{"issue":"9","key":"11991_CR84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41568-025-00847-2","volume":"25","author":"VF Gomerdinger","year":"2025","unstructured":"Gomerdinger VF, Nabar N, Hammond PT (2025) Advancing engineering design strategies for targeted cancer nanomedicine. Nat Rev Cancer 25(9):657\u2013683","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11991_CR85","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L et al (2023) Smart nanoparticles for cancer therapy. Signal Transduct Target Ther 8(1):418","journal-title":"Signal Transduct Target Ther"},{"key":"11991_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28186624","author":"S Malik","year":"2023","unstructured":"Malik S, Muhammad K, Waheed Y (2023) Emerging applications of nanotechnology in healthcare and medicine. Molecules Basel. https:\/\/doi.org\/10.3390\/molecules28186624","journal-title":"Molecules Basel"},{"key":"11991_CR87","doi-asserted-by":"publisher","first-page":"8095","DOI":"10.2147\/IJN.S208540","volume":"14","author":"A Patra","year":"2019","unstructured":"Patra A, Satpathy S, Hussain MD (2019) Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells. Int J Nanomed 14:8095\u20138104","journal-title":"Int J Nanomed"},{"issue":"2","key":"11991_CR88","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7150\/ijbs.76187","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Targeting Breast Cancer Stem Cells. Int J Biol Sci 19(2):552\u2013570","journal-title":"Int J Biol Sci"},{"key":"11991_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163906","author":"RA Glabman","year":"2022","unstructured":"Glabman RA, Choyke PL, Sato N (2022) Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14163906","journal-title":"Cancers (Basel)"},{"key":"11991_CR90","doi-asserted-by":"publisher","first-page":"1441820","DOI":"10.3389\/fimmu.2024.1441820","volume":"15","author":"M Stavrou","year":"2024","unstructured":"Stavrou M, Constantinidou A (2024) Tumor associated macrophages in breast cancer progression: implications and clinical relevance. Front Immunol 15:1441820","journal-title":"Front Immunol"},{"key":"11991_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24050899","author":"A Liskova","year":"2019","unstructured":"Liskova A et al (2019) Dietary phytochemicals targeting cancer stem cells. Molecules. https:\/\/doi.org\/10.3390\/molecules24050899","journal-title":"Molecules"},{"key":"11991_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030713","author":"KJ Chiu","year":"2022","unstructured":"Chiu KJ et al (2022) Natural compounds targeting cancer-associated fibroblasts against digestive system tumor progression: therapeutic insights. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030713","journal-title":"Biomedicines"},{"key":"11991_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121652","author":"S Paudel","year":"2023","unstructured":"Paudel S, Mishra N, Agarwal R (2023) Phytochemicals as immunomodulatory molecules in cancer therapeutics. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16121652","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"11991_CR94","doi-asserted-by":"publisher","first-page":"e202402479","DOI":"10.1002\/cbdv.202402479","volume":"22","author":"AAA Aljabali","year":"2025","unstructured":"Aljabali AAA et al (2025) Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment. Chem Biodivers 22(8):e202402479","journal-title":"Chem Biodivers"},{"key":"11991_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/nu15081896","author":"A Rudzi\u0144ska","year":"2023","unstructured":"Rudzi\u0144ska A et al (2023) Phytochemicals in cancer treatment and cancer prevention-review on epidemiological data and clinical trials. Nutrients. https:\/\/doi.org\/10.3390\/nu15081896","journal-title":"Nutrients"},{"key":"11991_CR96","doi-asserted-by":"publisher","first-page":"105293","DOI":"10.1016\/j.tiv.2021.105293","volume":"79","author":"D Singh","year":"2022","unstructured":"Singh D et al (2022) Nimbolide-encapsulated PLGA nanoparticles induces Mesenchymal-to-Epithelial Transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells. Toxicol Vitro 79:105293","journal-title":"Toxicol Vitro"},{"issue":"4","key":"11991_CR97","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1021\/acsabm.1c00141","volume":"4","author":"D Singh","year":"2021","unstructured":"Singh D et al (2021) Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer. ACS Appl Bio Mater 4(4):3670\u20133685","journal-title":"ACS Appl Bio Mater"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11991-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:03:17Z","timestamp":1779807797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11991-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11991"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11991-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}